Welcome to LookChem.com Sign In|Join Free

CAS

  • or

357436-78-3

Post Buying Request

357436-78-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

357436-78-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 357436-78-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,7,4,3 and 6 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 357436-78:
(8*3)+(7*5)+(6*7)+(5*4)+(4*3)+(3*6)+(2*7)+(1*8)=173
173 % 10 = 3
So 357436-78-3 is a valid CAS Registry Number.

357436-78-3Relevant articles and documents

Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3- benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity

Kettler, Katja,Wiesner, Jochen,Silber, Katrin,Haebel, Peter,Ortmann, Regina,Sattler, Isabel,Dahse, Hans-Martin,Jomaa, Hassan,Klebe, Gerhard,Schlitzer, Martin

, p. 93 - 101 (2007/10/03)

Water solubility was previously found to be essential for in vivo-antimalarial activity of a novel type of benzophenone-based farnesyltransferase inhibitors. Introduction of a α-amino group into the phenylacetic acid substructure provided more soluble compounds with high farnesyltransferase inhibitory activity. The in vitro-antimalarial activity was detrimentally influenced by this structural modification.

Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-Acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides

Wiesner, Jochen,Kettler, Katja,Jomaa, Hassan,Schlitzer, Martin

, p. 543 - 545 (2007/10/03)

We have described 5-(4-propoxycinnamoylamino)-2-(4-tolylacetylamino)benzophenone 6e as a novel lead for anti-malarial agents. Anti-malarial activity of these 5-(4-propoxycinnamoylamino)benzophenones proved to be quite sensitive against variations of the a

Synthesis, molecular modeling, and structure - Activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors

Sakowski,B?hm,Sattler,Dahse,Schlitzer

, p. 2886 - 2899 (2007/10/03)

Because of the involvement of farnesylated proteins in oncogenesis, inhibition of the protein-modifying enzyme farnesyltransferase is considered a major emerging strategy in cancer therapy. Here, we describe the structure - activity relationship of a nove

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 357436-78-3